Multiple high potency TEADi have now been developed and subsequently entered clinical trials for cancers such as mesothelioma, as well as other cancers that harbor NF2 mutations or oncogenic YAP gene fusions (Calses et al, 2019; Dey et al, 2020; Pobbati et al, 2023). The gene discussed is NF2; the disease is mesothelioma.